All lobbying filings

ARNOLD & PORTER KAYE SCHOLER LLP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $70,000.00 income · posted Jul 18, 2025

Official filing document

Bills named in this filing 2

HR 4818
Treat and Reduce Obesity Act of 2023
S 2407
Treat and Reduce Obesity Act of 2023

Lobbying activity 4

Pharmacy

Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding.

Health Issues

Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).

Consumer Issues/Safety/Products

Issues related to general compounding.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.